ArticleDiagnostics (Basel, Switzerland)2021
Clues to Disease Activity in Juvenile Dermatomyositis: Neopterin and Other Biomarkers.
Article in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Neutrophil lymphocyte ratio as a marker of skin disease activity in older children with juvenile dermatomyositis.Pediatric rheumatology online journal · 2025Article
- Juvenile dermatomyositis: new insights into pathogenesis and clinical applications.Pediatric rheumatology online journal · 2025Review
- Discovery of tissue-specific proteomic signatures in juvenile dermatomyositis highlights pathways reflecting persistent disease activity, clinical heterogeneity, and myositis-specific autoantibody subtype.Annals of the rheumatic diseases · 2025Article
- Expert Perspective: Diagnostic Approach to Differentiating Juvenile Dermatomyositis From Muscular Dystrophy.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
- Monozygotic twins discordant for juvenile dermatomyositis: clinical, serological and gene expression studies.Pediatric rheumatology online journal · 2025Article
- The emerging role of growth differentiation factor 15 as a potential disease biomarker in juvenile dermatomyositis.Rheumatology (Oxford, England) · 2025Article
- Decreased Peripheral Blood Natural Killer Cell Count in Untreated Juvenile Dermatomyositis Is Associated with Muscle Weakness.International journal of molecular sciences · 2024Article
- Increased percentage of HLA-DR T cells in untreated juvenile dermatomyositis.Clinical immunology communications · 2024Article
- Artificial intelligence for nailfold capillaroscopy analyses - a proof of concept application in juvenile dermatomyositis.Pediatric research · 2024Article
- Interferon type I signature associated with skin disease in juvenile dermatomyositis.Frontiers in medicine · 2024Article
- Juvenile dermatomyositis: association between nail fold capillary end row loop- area under the curve- and disease damage indicators.Pediatric rheumatology online journal · 2023Article
- Macrophage activation syndrome in juvenile dermatomyositis: a case report and a comprehensive review of the literature.Pediatric rheumatology online journal · 2023Review
- Juvenile Dermatomyositis: Association between Nail Fold Capillary End Row Loops Area Under the Curve and Disease Damage Indicators.Research square · 2023Article
- B Cell Lymphocytosis in Juvenile Dermatomyositis.Diagnostics (Basel, Switzerland) · 2023Article
- Increased Otoferlin Expression in B Cells Is Associated with Muscle Weakness in Untreated Juvenile Dermatomyositis: A Pilot Study.International journal of molecular sciences · 2023Article
- The von Willebrand Factor Antigen Reflects the Juvenile Dermatomyositis Disease Activity Score.Biomedicines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Easily accessible biomarkers are urgently needed to evaluate immune activation in Juvenile Dermatomyositis (JDM). The goal of this retrospective study is to define immunological and clinical differences between untreated JDM patients with either normal or elevated (>10 mmol/L) levels of neopterin, a biomarker of macrophage activation. We included all JDM with neopterin data obtained before initiating medical therapy. We assessed T, B, NK cell populations, muscle enzymes, and disease activity scores for skin (sDAS), muscle (mDAS), total (tDAS), the duration of untreated disease, disease course, and myositis-specific antibody (MSA). Seventy-nine percent of 139 untreated JDM patients had elevated serum neopterin. The group with elevated neopterin had significantly more active disease: tDAS 11.9 vs. 8.1 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.